Cullinan Oncology

Deal terminate tear up end deal scrap

Biotech

Cullinan, after $25M deal, hands back bispecific to Harbour

The biotech said that “following a review of the data from the phase 1 study,” it now plans to discontinue development.

James Waldron Aug 8, 2024 10:10am

Graphic image of a compass above an unfolded map Orange background color

Cullinan rebrands, halts lymphoma trial in autoimmune refocus

Apr 16, 2024 10:05am

Photo of five sailboats setting out in the same direction over dark blue water

Cullinan plucks US rights to Harbour BioMed's novel bispecific

Feb 13, 2023 7:00pm